生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Puma Biotechnology
Announces Publication of
Alisertib
Abstract Titles for the 2024 ASCO Annual Meeting
2024-05-23
·
交易
·
BioSpace
上市批准
引进/卖出
临床2期
ASCO会议
临床1期
LOS ANGELES--(BUSINESS WIRE)--
Puma Biotechnology Inc.
(NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on
alisertib
to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and online from May 31-June 4. Full abstracts of the following posters are available online at . Abstract 1037: Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating
tumor
cells (CTCs) in TBCRC 041: A phase II study of
alisertib
in
endocrine resistant metastatic breast cancer (MBC)
Presenter: Karthik Giridhar, MD., Mayo Clinic Abstract 8572: Phase I/Ib study of the
aurora kinase A Inhibitor
aurora kinase A
Inhibitor
alisertib
in combination with
osimertinib
in advanced
osimertinib
-resistant
EGFR
-
mutated lung cancer
Presenter: Turja Chakrabarti, MD.,
University of California, San Francisco
About
Puma Biotechnology
:
Puma Biotechnology, Inc.
is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance
cancer
care.
Puma
in-licensed the global development and commercialization rights to
PB272
(
neratinib
, oral) in 2011.
Neratinib
, oral was approved by the
U.S. Food and Drug Administration
in July 2017 for the extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer
, following adjuvant
trastuzumab
-based therapy, and is marketed in the United States as
NERLYNX
® (
neratinib
) tablets. In February 2020,
NERLYNX
was also approved by the
FDA
in combination with
capecitabine
for the treatment of adult patients with
advanced or metastatic HER2-positive breast cancer
who have received two or more prior anti- HER2-based regimens in the metastatic setting.
NERLYNX
was granted marketing authorization by the
European Commission
in September 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive
HER2-overexpressed/amplified breast cancer
and who are less than one year from completion of prior adjuvant
trastuzumab
-based therapy.
NERLYNX
® is a registered trademark of
Puma Biotechnology, Inc.
In September 2022,
Puma
entered into an exclusive license agreement for the development and commercialization of the anti-
cancer
drug
alisertib
, a selective, small molecule, orally administered inhibitor of
aurora kinase A
. Initially,
Puma
intends to focus the development of
alisertib
on the treatment of
small cell lung cancer
and
breast cancer
. In February 2024,
Puma
initiated ALISCA-Lung 1, a Phase II clinical trial of
alisertib
monotherapy for the treatment of patients with
extensive-stage small cell lung cancer
. Further information about
Puma Biotechnology
Puma
Biotechnology may be found at .
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Puma Biotechnology, Inc.
The University of California, San Francisco
US Food & Drug Administration
[+1]
适应症
癌症
转移性乳腺癌
肺癌
[+5]
靶点
Aurora A
EGFR
BBC3
药物
Alisertib
CYC-3
甲磺酸奥希替尼
[+3]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务